VYNE Therapeutics Inc. financial data

Symbol
VYNE on Nasdaq
Industry
Pharmaceutical Preparations
Location
685 Route 202/206 N., Suite 301, Bridgewater, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Menlo Therapeutics Inc. (to 9/2/2020), Menlo Therapeutics, Inc. (to 1/31/2018), Tigercat Pharma, Inc. (to 1/7/2013)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 880 %
Debt-to-equity 14.2 % -50%
Return On Equity -44 % +64%
Return On Assets -38.5 % +59.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.7M shares +350%
Common Stock, Shares, Outstanding 14.5M shares +343%
Entity Public Float 13.1M USD -41.3%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 42.6M shares +1201%
Weighted Average Number of Shares Outstanding, Diluted 42.6M shares +1201%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 486K USD +19.4%
Research and Development Expense 17.4M USD -12.3%
General and Administrative Expense 3.29M USD +2.11%
Costs and Expenses 31.3M USD -7.64%
Operating Income (Loss) -30.8M USD +7.97%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -27.9M USD +14.7%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -28.4M USD +19%
Earnings Per Share, Basic 1.68 USD/shares +92.9%
Earnings Per Share, Diluted 1.68 USD/shares +92.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29.6M USD +43.5%
Marketable Securities, Current 48.5M USD
Cash, Cash Equivalents, and Short-term Investments 31M USD -27.7%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD -46.9%
Inventory, Net 0 USD -100%
Assets, Current 83.8M USD +265%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 151K USD
Assets 86.6M USD +247%
Employee-related Liabilities, Current 736K USD -12%
Accrued Liabilities, Current 5.07M USD +15.8%
Liabilities, Current 11.8M USD +84.4%
Operating Lease, Liability, Noncurrent 25K USD
Liabilities 11.8M USD +53.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -58K USD
Retained Earnings (Accumulated Deficit) -707M USD -4.19%
Stockholders' Equity Attributable to Parent 74.9M USD +333%
Liabilities and Equity 86.6M USD +247%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.98M USD -45.7%
Net Cash Provided by (Used in) Financing Activities -217K USD -114%
Net Cash Provided by (Used in) Investing Activities -3.57M USD -171%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 14.5M shares +343%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.6M USD -1563%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.7M USD +43.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 89.8M USD +3.34%
Deferred Tax Assets, Gross 89.8M USD +3.34%
Operating Lease, Liability 214K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.39M USD +6.6%
Lessee, Operating Lease, Liability, to be Paid 228K USD -24%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 120K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 102K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 126K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14K USD
Deferred Tax Assets, Operating Loss Carryforwards 72.5M USD -0.54%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares
Unrecognized Tax Benefits 2.46M USD -13.9%
Additional Paid in Capital 782M USD +12.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.44M USD -13.3%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%